Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.

Novo Nordisk (CPSE:NOVO B) is back in focus after the European Commission granted marketing authorisation for its once daily Wegovy pill across all EU member states, creating a new oral option in GLP 1 obesity treatment.

See our latest analysis for Novo Nordisk.

The Wegovy pill approval lands at a time when Novo Nordisk’s 90 day share price return of 23.22% suggests momentum is still building, even as the year to date share price return is down 3.01% and the 1 year total shareholder return has declined 25.03%.

If this obesity breakthrough has you thinking more broadly about healthcare opportunities, it is worth scanning other potential ideas in our healthcare focused screener for 128 healthcare AI stocks.

After a 23.22% gain over 90 days, alongside a 25.03% decline over 1 year and a share price now slightly above the average analyst target, does Novo Nordisk’s current valuation still offer an attractive balance of risk and reward?

Most Popular Narrative: 11.6% Overvalued

According to the most followed narrative on Novo Nordisk, the fair value sits at DKK287 against the last close of DKK320.30, which frames today’s pricing as richer than that fair value line.

Novo Nordisk’s business model is straightforward. It develops hormone-based therapies, protects them with patents, manufactures them at scale, and sells them at high margins into reimbursed healthcare systems. In obesity, GLP-1 drugs such as Wegovy transformed the company into a perceived structural growth leader. The stock was priced for durable dominance. The pullback reflects emerging limits to that assumption.

Read the complete narrative.

This narrative leans heavily on how long obesity growth can run, what reimbursement really supports, and which earnings multiple those cash flows might justify.

Result: Fair Value of DKK287 (OVERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, Novo Nordisk’s obesity story could look different if coverage for Wegovy broadens more quickly or if manufacturing constraints ease sooner than expected.

Find out about the key risks to this Novo Nordisk narrative.

Another View on Novo Nordisk: Earnings Multiple Signals Underpricing

The user narrative pegs Novo Nordisk as 11.6% overvalued at DKK287, yet the current DKK320.30 price implies a P/E of 11.6x. That is markedly lower than peers at 24.8x, the European pharmaceuticals average at 21.9x, and an estimated fair ratio of 22.8x. If the market ever moves closer to that fair ratio, is today’s discount a cushion against narrative risk or a value trap in disguise?

See what the numbers say about this price — find out in our valuation breakdown.

CPSE:NOVO B P/E Ratio as at Jul 2026 CPSE:NOVO B P/E Ratio as at Jul 2026 Next Steps

With sentiment clearly divided around Novo Nordisk, now is a good time to move quickly, review the underlying data for yourself, and weigh up the 3 key rewards and 4 important warning signs.

Looking For More Investment Ideas Beyond Novo Nordisk?

If Novo Nordisk has sharpened your focus on quality opportunities, do not stop here. Use the Simply Wall St screener to keep your watchlist working for you.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NOVO-B.CO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com